Press Releases

07/27/2015

SeraCare Life Sciences Announces Strategic Partnership with ViveBio to EnableNext Generation Preanalytic Products for the IVD Industry

Combined Technologies Offer IVD Developers New Tools for Collection, Stabilization and QC

07/08/2015

SeraCare Life Sciences’ Precision Medicine Unit Launches New Product to Ensure Accuracy of NGS Assays

SeraCare Life Sciences, a leading partner to global in vitro diagnostics manufacturers, today announced that the company’s new precision medicine business unit has launched its first product, the Seraseq™ Solid Tumor Mutation Mix—I (AF20); a biosynthetic reference material designed to evaluate the performance of next generation sequencing (NGS)-based tumor profiling assays.

06/26/2015

SeraCare Life Sciences Signs CRADA with NCI to Advance Cancer Diagnostics

SeraCare Life Sciences, a leading partner to global in vitro diagnostics manufacturers, today announced that it has signed a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI), part of the National Institutes of Health, to create reference materials and positive controls for cancer assays.

06/18/2015

SeraCare Makes Key Investment in Expanding R&D Facility; Strengthens Leadership with New Hires

SeraCare Life Sciences, a leading partner to global In Vitro Diagnostics manufacturers, announced today an expansion and upgrade to their Gaithersburg, MD, R&D facility.

06/05/2015

SeraCare Life Sciences Announces Formation of Precision Medicine Unit; Bolsters Leadership with Key Industry Hire

SeraCare Life Sciences, a leading partner to global In Vitro Diagnostics manufacturers, announced the formation of a new business unit focused on the development of technologies and products to help enable the safe and effective expansion of precision medicine-driven diagnostics.